2-(苄氧基)吡啶-4-硼酸 | 1256355-62-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-(苄氧基)吡啶-4-硼酸
• 英文名称: (2-(benzyloxy)pyridin-4-yl)boronic acid
• 英文别名: (2-benzyloxy-4-pyridyl)boronic acid；2-(Benzyloxy)pyridine-4-boronic acid；(2-phenylmethoxypyridin-4-yl)boronic acid
• CAS: 1256355-62-0
• 化学式: C₁₂H₁₂BNO₃
• 分子量: 229.043
• InChiKey: RBEGAHHNAGUVBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.34
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  62.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(苄氧基)吡啶-4-硼酸 在 四(三苯基膦)钯 、 palladium 10% on activated carbon 、 氢气 、 sodium carbonate 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 38.0h， 生成 ethyl 3-(2-chloropyridin-4-yl)benzoate
  参考文献：
  名称：

  [EN] HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF
  [FR] COMPOSÉS HÉTÉROARYLES SERVANT D'INHIBITEURS D'IRAK, ET LEURS UTILISATIONS

  摘要：

  本发明涉及式(I)化合物及其药用可接受的组合物，作为IRAK抑制剂。

  公开号：

  WO2017049068A1

文献信息

• [EN] AZAINDOLE DERIVATIVES WHICH ACT AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS D'AZAINDOLE AGISSANT COMME INHIBITEUR DE PI3K
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2014011568A1

  公开（公告）日：2014-01-16

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating immunological disorders, cardiovascular disease, cancer, and other diseases, disorders or conditions associated with PI3Kδ.

  揭示了Formula 1的化合物及其药用盐，其中R1、R2、R3、R4、R5、R6、R7、R8、R9和R10在规范中有定义。本公开还涉及制备Formula 1化合物的材料和方法，含有它们的药物组合物，以及它们用于治疗免疫性疾病、心血管疾病、癌症和与PI3Kδ相关的其他疾病、疾患或症状的用途。
• Design and Synthesis of Novel Aminoindazole-pyrrolo[2,3-b]pyridine Inhibitors of IKKα That Selectively Perturb Cellular Non-Canonical NF-κB Signalling
  作者：Christopher Riley、Usama Ammar、Aisha Alsfouk、Nahoum G. Anthony、Jessica Baiget、Giacomo Berretta、David Breen、Judith Huggan、Christopher Lawson、Kathryn McIntosh、Robin Plevin、Colin J. Suckling、Louise C. Young、Andrew Paul、Simon P. Mackay

  DOI：10.3390/molecules29153515

  日期：——

  The inhibitory-kappaB kinases (IKKs) IKKα and IKKβ play central roles in regulating the non-canonical and canonical NF-κB signalling pathways. Whilst the proteins that transduce the signals of each pathway have been extensively characterised, the clear dissection of the functional roles of IKKα-mediated non-canonical NF-κB signalling versus IKKβ-driven canonical signalling remains to be fully elucidated. Progress has relied upon complementary molecular and pharmacological tools; however, the lack of highly potent and selective IKKα inhibitors has limited advances. Herein, we report the development of an aminoindazole-pyrrolo[2,3-b]pyridine scaffold into a novel series of IKKα inhibitors. We demonstrate high potency and selectivity against IKKα over IKKβ in vitro and explain the structure–activity relationships using structure-based molecular modelling. We show selective target engagement with IKKα in the non-canonical NF-κB pathway for both U2OS osteosarcoma and PC-3M prostate cancer cells by employing isoform-related pharmacodynamic markers from both pathways. Two compounds (SU1261 [IKKα Ki = 10 nM; IKKβ Ki = 680 nM] and SU1349 [IKKα Ki = 16 nM; IKKβ Ki = 3352 nM]) represent the first selective and potent pharmacological tools that can be used to interrogate the different signalling functions of IKKα and IKKβ in cells. Our understanding of the regulatory role of IKKα in various inflammatory-based conditions will be advanced using these pharmacological agents.